NASD · Healthcare · Biotechnology · Switzerland
MoonLake Immunotherapeutics is a small cap company (market value between $300 million and $2 billion) in the Biotechnology industry.
MoonLake Immunotherapeutics is a clinical stage biotechnology company developing SLK, a tri-specific inhibitor of IL-17A and IL-17F, for inflammatory skin and joint diseases. The company is advancing SLK through clinical trials in hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and palmoplantar pustulosis in dermatology and rheumatology patients.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the MoonLake Immunotherapeutics stock.
Not valued: We cannot value this company yet.
8 more funds hold it; the full list is part of the paid plan.
134 more in this industry show a wider margin of safety.
We do not publish a verdict on MLTX yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.
We do not publish one (as of the 2026-10-30 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.